Science
Mechanism of Action
As a synthetic estrogen receptor agonist, ethinylestradiol mimics natural estrogen. When administered systemically, it influences hormonal pathways to reduce ovarian androgen production, elevate sex hormone-binding globulin (SHBG), and decrease 5-alpha-reductase activity, thereby diminishing overall androgen levels and subsequently lowering sebum output, which is beneficial for acne management. Estrogens are also suggested to contribute to skin protection against UVB radiation and modulate melanogenesis.
Research
Clinical Evidence
Low confidenceN/A
Key findings
- 01 A topical application of 0.01% ethinylestradiol combined with 2% minoxidil for female pattern hair loss demonstrated some improvement, though it did not offer a statistically significant advantage over minoxidil 2% alone. This combination also correlated with increased menstrual irregularities. Further research with lower concentrations and alternative pharmacological formulations is advised for topical applications.
Transparency
Dusting Analysis
Ethinylestradiol is classified as a potent pharmaceutical agent with significant hormonal activity, primarily regulated for use in prescription medications like oral contraceptives. It is not typically permitted as a cosmetic ingredient due to its systemic effects, even at low topical concentrations, which can include adverse reactions such as menstrual irregularities. Its use in any cosmetic formulation would constitute a significant regulatory and safety red flag.
The Formula
Formulation
Stability
This compound exhibits low aqueous solubility (4.8-11.3 mg/L) and is unstable in aqueous solutions for extended periods (beyond one day). For optimal solubility in aqueous buffers, initial dissolution in ethanol followed by dilution is recommended. It readily dissolves in various organic solvents including ethanol, ether, acetone, chloroform, and vegetable oils.
Safety
Safety Profile
Ethinylestradiol is a potent synthetic estrogen approved by the FDA primarily in combination oral contraceptives for pregnancy prevention and the treatment of acne in women desiring contraception. The European Medicines Agency (EMA) advises its use for moderate acne only when other treatments have failed and in women opting for oral contraception. Due to its significant hormonal activity and potential for systemic effects, it is strictly considered a pharmaceutical ingredient and not suitable for cosmetic applications. Oral administration is associated with numerous drug interactions. Topical application at 0.01% has been linked to menstrual irregularities.
Your Skin
Skin Compatibility
Our Assessment
Verdict
Given its classification as a potent pharmaceutical with significant hormonal and systemic effects, even at low topical concentrations, Ethinylestradiol is unsuitable and should be avoided in cosmetic formulations.
Related
Similar Ingredients
Finding similar ingredients…